A cis eQTL contains a genetic variant that alters expression of a nearby gene. eQTLs are ubiquitous across the genome 1 and while most are stable across tissues and conditions, environmental perturbations can alter a minority of them [2] [3] [4] [5] [6] [7] [8] . If a perturbation disrupts upstream regulatory mechanisms for a gene then it could magnify or dampen an eQTL effect, resulting in an environmental interaction. Therefore, if we observe a set of eQTL interactions due to a perturbagen (such as a drug), shared upstream regulatory mechanisms may represent key affected pathways. As the regulatory genome is mapped 9, 10 , this approach to define environmental mechanisms will become more potent.
A clinical trial is an ideal cohort to detect eQTL interactions with drugs or other environmental perturbations and could lead to key insights about mechanisms of action.
In a clinical trial, homogenous groups of subjects are randomly exposed to a drug in a structured study design that frequently includes biological samples collected at different time points with extensive clinical and physiological phenotyping. If RNA is queried at multiple time points under different exposure states, we speculated that repeat measurements could increase power to detect not only eQTLs, but also their interactions.
As a proof of principle, we looked at the modulation of eQTL effects by anti-IL-6 exposure using data from a phase II clinical trial to evaluate the safety and efficacy of a neutralizing IL-6 monoclonal antibody (PF-04236921) in 157 SLE patients 11 (Online Methods). Here, our clinical outcome of interest is a reduction in free IL-6 protein levels. We conducted whole blood high-depth RNA-seq profiling at 0, 12, and 24 weeks in anti-IL-6 exposed and unexposed individuals with the Illumina TruSeq protocol. We observed and quantified 20,253 gene features and genotyped 608,017 variants genomewide (Online Methods). Along with each RNA-seq assay, we documented drug exposure and quantified cell counts with FACS and IFN signature status with real-time PCR.
We first mapped cis eQTLs (SNPs within 250kb of the transcription start site of the gene) and then tested those eQTLs for interactions with cell counts, IFN status and drug exposure. eQTL interactions can be explored using our interactive visualization tool (http://baohongz.github.io/Lupus_eQTL).
We used a linear mixed model, including repeat measurements with up to three RNAseq assays per patient (Fig. 1a, 379 (Fig. 1d) . For each of the 4,976 cis eQTL genes, we tested the most significantly associated SNP for environmental interactions.
We first tested a type of eQTL interactions that have been examined previously: cell counts 12, 13 . We obtained FACS data for 320 samples for which we had contemporaneous RNA-seq profiles (n=152 subjects). We determined the percentage of total lymphocytes that were T cells by gating (Fig. 2a) 2b, p=1/1,001 = <0.001).
Interactions can be divided into magnifiers, where environmental exposure and eQTL effects are in the same direction, and dampeners where the effects work in the opposite direction ( Supplementary Fig. 1, Fig. 2c ). The NOD2 rs1981760 eQTL is an example of an interaction that is dampened by T cell count (Fig. 2d, p=6 .5x10 -5 ), and has separately been shown to vary across cell types 12, 13 . For each percent increase in T cell proportion, the eQTL effect is reduced by 0.008 log 2 (cpm+1).
Many patients with SLE exhibit high levels of genes induced by IFN alpha; these genes, known as the IFN signature, are a marker of disease severity 14, 15 . We explored the influence of IFN alpha on gene regulation after determining the IFN status of every patient at each time point using real-time PCR of 11 IFN-inducible genes 16 (Online Methods, Fig. 3a) . We identified 185 IFN-eQTL interactions with p<0.01
(Supplementary Table 1 ). Following the same permutation procedures as above, our observed interactions were unlikely to have occurred by chance (maximum permutation interactions=112, p<0.001) (Supplementary Fig. 2 ). We note that interactions with a proxy gene for IFN status have been described 1 and we find overlap of genes with those reported interactions ( Supplementary Fig. 3 ). For example, SLFN5 expression is influenced by the rs12945522 SNP (1.3x10 -10 , Fig. 3b ). This effect is magnified in IFN high samples.
To define transcription factors that drive the response to IFN alpha, we sought to identify motifs that explain the differences between magnifier and dampener eQTLs ( Supplementary Fig. 4 ). We applied HOMER 17 Table 2 ). An example is the GTF2A2 rs2306355 eQTL (p=8.7x10
is in tight LD (r 2 =0.82 in Europeans) with rs6494127, which interrupts the GAAA core of the IRF1 motif ( Fig. 3c) , and likely disrupts IRF1 binding 18 . We observe greater expression in individuals with the rs2306355 A allele compared to G; this difference is dampened in IFN low individuals (Fig. 3d) .
We then examined whether IL-6 blockade alters the relationship between genomic variation and gene expression and induces drug-eQTL interactions. We observed 126 drug-eQTL interactions with p<0.01 (Supplementary Table 1 ). Following the same permutation strategy as above, we found a median of 77 interactions with p<0.01 (maximum=117) from 1,000 permutations. This suggests that about half of our drugeQTL interactions likely represent real biological phenomena, and not statistical artifact ( Supplementary Fig. 5 ). These drug-eQTL interactions showed little overlap with the interactions observed for T cell count or IFN status ( Supplementary Fig. 6 ). Again, these interactions can be divided into magnifiers and dampeners ( Supplementary Fig.   7 ). Figure 4a highlights one of the most significant drug-eQTL interactions (p=6.5x10 -4 ) for the gene KIAA2013. Of particular biological relevance is an interaction with IL10, an anti-inflammatory cytokine (Supplementary Fig. 8 ).
A more common strategy to determine the effect of a perturbagen is to use differential gene expression. For differential expression following drug treatment, we identified 1,161 genes with nominal statistical evidence (p<0.01) but modest effects (max fold change=1.3, Supplementary Fig. 9 ). Furthermore, only 8/126 drug-eQTL interaction genes also show evidence of differential gene expression. This suggests that eQTL interactions offer independent information from differential expression, which might contribute to defining mechanisms.
To validate these interactions, we hypothesized that interactions due to drug exposure are likely driven by free IL-6 cytokine levels (our key clinical biomarker of interest). If this is the case, for eQTLs dampened by drug exposure, an increase in free IL-6 should elicit an opposite interaction effect and result in eQTL magnification. We assessed whether eQTL interactions with free IL-6 protein levels measured in the patient serum samples were consistent with those following IL-6 blockade. We observed enrichment in the overlap between cytokine interactions and drug interactions (91/126 interactions in consistent direction, Figure 4b , p=3.2x10 -7 , binomial test). We were concerned that free IL-6 and drug exposure are not independent in this dataset, and that this concordance might be in part due to the connection between free IL-6 protein levels and IL-6 blockade ( Supplementary Fig. 10 ). To assess whether free IL-6 offers independent interaction effects that were consistent after accounting for drug effect, we modeled free IL-6 levels based on the presence or absence of drug and then assessed interactions with residual IL-6 levels. Again, we observed a significant number of interactions in a consistent direction (p=0.03 Supplementary Fig. 11 ).
For many biologic medications, predictive pharmacogenetics has been challenging; for example, studies to define genetic or non-genetic biomarkers of anti-TNF response have not been successful 19, 20 . Identifying relevant SNP-gene pairs from eQTL interactions could offer an alternative molecular strategy to assess effective drug response in patients. We speculated that these drug-eQTL interactions could be used in a clinical pharmacogenetic context to assess effective drug exposure for patients.
We defined a simple drug exposure score using the 126 drug-eQTL interactions (Online Methods). For each RNA-seq sample, we assessed whether the expression of the interaction gene was more consistent with the drug exposed or unexposed state for the corresponding interaction SNP genotype. Samples more consistent with the drugexposed state are assigned a larger drug exposure score. Unsurprisingly, we found a difference in drug exposure score between the unexposed and exposed samples (Supplementary Fig. 12 ) (r s =0.79, p=6.9x10 -81 ); these differences reflect the fact that the eQTLs were themselves identified by examining samples with and without drug exposure. However, while we did not utilize actual drug dose to identify drug-eQTL interactions, we found a significant correlation between drug dose (10, 50 or 200mg) and drug exposure score (r s =0.16, p=0.018) in the drug-exposed samples (Fig. 4c) .
Hence scores based on eQTL interactions might reflect the biological activity that a medication is having upon an individual, and may be modeling an effective medication activity level. Such a scoring system could be implemented easily in most phase III trials, where the numbers of samples are far in excess of this phase II trial, ensuring better powered and more accurate eQTL-interaction mapping. Such a strategy might be even more effective if appropriate cell-types or affected tissues were queried and could be modeled in conjunction with differential expression to obtain more power.
Defining the downstream mechanism influenced by a drug is critical and might be a path 
RNA-sequencing
Peripheral venous blood samples were collected in PAXgene Blood RNA tubes (PreAnalytiX GmbH, BD Biosciences) for high-depth RNA-seq profiling at 0, 12, and 24 weeks. Total RNA was extracted from blood samples using the PAXgene Blood RNA kit (Qiagen) at a contract lab using a customized automation method. The yield and quality of the isolated RNA were assessed using Quant-iT™ RiboGreen® RNA Assay Kit (ThermoFisher Scientific) and Agilent 2100 Bioanalyzer (Agilent Technologies),
respectively. Following quality assessment, the RNA was sent to another contract lab for RNA sequencing: an aliquot of 500-1000 ng of each RNA was processed with a GlobinClear kit, Human (ThermoFisher Scientific) to remove globin mRNA. After globin mRNA depletion, the RNA samples were converted to cDNA libraries using TruSeq RNA Sample Prep Kit v2 (Illumina) and sequenced using Illumina HiSeq 2000
sequencers. An average of 40M 100bp pair-end reads were generated per sample for downstream analysis.
468 RNA-seq profiles were generated from 180 patients. Data were aligned to the reference genome and gene expression quantified using Subread 21 and featureCounts 22 respectively. The genes with mapped reads were filtered so only those with at least 10 reads (CPM>0.38) in at least 32 samples (minimum number of patients with both unexposed and exposed RNA-seq assays in a drug group) were retained prior to normalization. 20,253 transcripts were normalized using the trimmed mean of Mvalues method and the edgeR R package 23 . Following quality control (QC), 4 samples were removed as outliers. Expression levels are presented as log 2 (cpm +1).
Genotyping

individuals were genotyped across 964,193 variants genome-wide with the Illumina
HumanOmniExpressExome-8v1.2 beadchip. SNPs were removed if they deviated from
Hardy-Weinberg Equilibrium (p < 1x10 -7 ), had a minor allele frequency <5%, missingness >2% or a heterozygosity rate greater than 3 standard deviations from the mean (PLINK 24, 25 ). For mapping eQTLs, SNPs on the Y chromosome were removed.
Following QC, 608,017 variants were used for further analysis. One sample had high missingness and was an outlier for heterozygosity rate so was removed from further analysis.
Cell counts
Blood samples were collected for cytometry analysis at weeks 0, 12 and 24. Samples were subjected to flow cytometry for T cell immunophenotyping. T cells (CD3+) were counted as a percentage of lymphocytes (CD45+). FACS data were available for 320 samples from 152 subjects.
Interferon status
The IFN status was classified using the expression of IFN response genes at each time point. The expression of 11 genes (HERC5, IFI27, IRF7, ISG15, LY6E, MX1, OAS2, OAS3, RSAD2, USP18, GBP5) 16 was measured using TaqMan Low Density Arrays.
Samples were classified as high or low IFN based on the first PCA score for the expression of these genes (Fig. 3a) . IFN status was available for 376 samples from 157 subjects.
Drug exposure
Samples were assigned as unexposed (placebo or week 0 samples) or drug exposed (week 12 and week 24 samples in the drug groups). When included in the model, unexposed samples were assigned as 0 and exposed samples as 1.
Free IL-6 protein levels
Free IL-6 protein levels were determined from serum using a commercial sandwich ELISA selected for binding only free IL-6. The assay was validated according to FDA biomarker and fit-for purpose guidelines. Free IL-6 protein levels were available for 311 samples from 145 subjects. Samples were ranked in order of IL-6 protein levels and included in the model to identify cytokine-eQTL interactions.
Statistical analysis eQTL and interaction analysis
157 patients (with 379 RNA-seq samples) had good quality gene expression and genotyping data for eQTL analysis. All statistical analyses were carried out in R 26 .
We defined a cis eQTL as the SNP within 250kb either side of the GENCODE 27 transcription start site of the gene. We first applied a linear model for the first available time point to identify each eQTL using the first 25 principal components of gene expression and the first 5 principal components of genotyping as covariates. SNPs were encoded as 0, 1 and 2. To adjust for multiple testing during eQTL discovery we used a corrected p-value threshold of 2.3x10 -8 (0.05/ 2,177,889 tests).
To map eQTLs using multiple samples for each individual, we applied a random intercept linear mixed model using the first 25 principal components of gene expression and the first 5 principal components of genotyping as covariates and patient as a random effect:
Where E i,j is gene expression for the i th sample from the j th subject, θ is the intercept, β geno is the genotype effect (eQTL), (κ j |i) is the random effect for the i th sample from the j th subject, pc i,l is principal component l of gene expression for sample i, pc j,m is principal component m of genotyping for subject j.
We used the most significant SNP (with p<2.3x10 -8 ) from the 4,976 identified eQTL genes to explore eQTL interactions. For each environmental interaction analysis, we further filtered these eQTLs to include only those with at least two individuals homozygous for the minor allele of the SNP being tested in each of the environmental factor groups. For example we required two of these individuals in each of the drug exposed and drug unexposed groups. To identify eQTL interactions, we added an additional covariate to the model for example drug exposure, and an interaction term between this covariate and the genotype of the SNP:
Where E i,j is gene expression for the i th sample from the j th subject, θ is the intercept, β geno is the genotype effect (eQTL), (κ j |i) is the random effect for the i th sample from the j th subject, pc i,l is principal component l of gene expression for sample i, pc j,m is principal component m of genotyping for subject j, β drug is the drug effect (differential gene expression) and β x is the interaction effect.
A p-value for the interaction term was determined with a likelihood ratio test.
To confirm the relative enrichment of eQTL interactions, we shuffled the interaction covariate (for example drug exposure) 1,000 times and calculated the number of 
Magnifiers and Dampeners
An eQTL interaction can either magnify or dampen the original eQTL effect. We multiplied the interaction z-score by the sign of the original eQTL effect (genotype beta) and defined magnifiers as interactions with an adjusted z-score > 0 and dampeners as interactions with an adjusted z-score < 0.
Differential gene expression analysis
To identify differentially expressed genes following drug exposure, we applied a random intercept linear mixed model using the first 25 principal components of gene expression and the first 5 principal components of genotyping as covariates and patient as a random effect.
Conditional analysis for IL-6 protein levels
We modeled the relationship between free IL-6 protein levels and drug exposure using a linear model. We used the residuals from this model in our interaction linear mixed model to identify IL-6 protein interactions independent of drug exposure.
Drug exposure score
We used linear discriminant analysis to assign a drug exposure score for each sample.
A score was calculated for each gene (see equation below) and then the final drug exposure score is the average across the 126 drug-eQTL genes.
Where G is gene expression for a given sample, G Unexp is predicted mean gene expression for unexposed samples of the relevant SNP genotype, G Exp is predicted mean gene expression for exposed samples of the relevant SNP genotype and SE is standard error for the intercept term of the model (unexposed expression for genotype 0).
HOMER analysis for transcription factor binding motif enrichment
We used the HOMER software suite 17 to look for enrichment of transcription factor binding motifs in the 185 IFN eQTL interactions (p<0.01). Each eQTL interaction was identified using the most highly associated SNP for that eQTL. However, as this SNP is not necessarily the functional SNP, we additionally considered all those with an r 2 1 0 2 . . .2 1 within 250kB of the transcription start site of the gene. We defined our motif search window as 20 bp on either side of each SNP (i.e.
bp wide).
We divided the eQTL interactions into magnifiers or dampeners and conducted two separate HOMER analyses: one with magnifiers in the foreground and dampeners in the background; the other with dampeners in the foreground and magnifiers in the background. HOMER reported the transcription factor motifs that were significantly enriched in the foreground relative to background. Motifs were plotted using the SeqLogo R library 29 .
A permutation p value for enrichment of the IRF1 transcription factor binding motif in IFN dampeners was determined as follows. The motif is interrupted by interaction SNPs (or SNPs in LD) corresponding to 11 dampening genes and 2 magnifying genes. We permuted which genes were labeled as magnifiers or dampeners 10,000 times and counted the number of genes in each category with an IRF1 motif interrupted. We found 18 occurrences from 10,000 trials with at least 11 dampening genes (p<0.002). 
